Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Methicillin-Resistant Staphylococcus aureus | 5 | 2023 | 62 | 2.210 |
Why?
|
| Staphylococcal Infections | 6 | 2023 | 65 | 2.050 |
Why?
|
| Rotavirus Vaccines | 6 | 2016 | 14 | 1.720 |
Why?
|
| Community-Acquired Infections | 4 | 2023 | 22 | 1.650 |
Why?
|
| Rotavirus Infections | 5 | 2016 | 17 | 1.590 |
Why?
|
| Gastroenteritis | 4 | 2016 | 18 | 1.490 |
Why?
|
| Carrier State | 2 | 2017 | 33 | 0.910 |
Why?
|
| Masks | 1 | 2023 | 15 | 0.800 |
Why?
|
| Georgia | 9 | 2023 | 189 | 0.780 |
Why?
|
| Anti-Bacterial Agents | 4 | 2023 | 415 | 0.780 |
Why?
|
| Rotavirus | 3 | 2016 | 14 | 0.650 |
Why?
|
| Pediatrics | 2 | 2013 | 69 | 0.630 |
Why?
|
| Child | 14 | 2023 | 3381 | 0.620 |
Why?
|
| Infant | 11 | 2021 | 1143 | 0.610 |
Why?
|
| Staphylococcus aureus | 5 | 2023 | 91 | 0.610 |
Why?
|
| Staphylococcal Skin Infections | 2 | 2017 | 10 | 0.560 |
Why?
|
| Electronic Health Records | 1 | 2019 | 99 | 0.550 |
Why?
|
| Soft Tissue Infections | 1 | 2017 | 6 | 0.530 |
Why?
|
| Child, Preschool | 10 | 2023 | 1516 | 0.490 |
Why?
|
| Antibodies, Neutralizing | 3 | 2025 | 118 | 0.480 |
Why?
|
| Vaccination | 2 | 2016 | 332 | 0.460 |
Why?
|
| Antibodies, Viral | 3 | 2025 | 295 | 0.430 |
Why?
|
| Humans | 34 | 2025 | 42163 | 0.430 |
Why?
|
| Health Personnel | 2 | 2013 | 262 | 0.380 |
Why?
|
| Ambulatory Care | 1 | 2013 | 81 | 0.370 |
Why?
|
| Health Status Disparities | 3 | 2023 | 705 | 0.370 |
Why?
|
| Lead Poisoning | 2 | 2023 | 25 | 0.370 |
Why?
|
| Information Systems | 1 | 2011 | 14 | 0.370 |
Why?
|
| Medicaid | 3 | 2020 | 138 | 0.350 |
Why?
|
| Lead | 2 | 2023 | 101 | 0.340 |
Why?
|
| Retrospective Studies | 6 | 2024 | 2485 | 0.330 |
Why?
|
| Case-Control Studies | 5 | 2017 | 1266 | 0.310 |
Why?
|
| Infant, Newborn | 4 | 2024 | 960 | 0.300 |
Why?
|
| Female | 18 | 2025 | 24018 | 0.300 |
Why?
|
| Male | 18 | 2025 | 22779 | 0.300 |
Why?
|
| Methicillin Resistance | 2 | 2007 | 11 | 0.300 |
Why?
|
| Abscess | 2 | 2017 | 10 | 0.260 |
Why?
|
| Emergency Service, Hospital | 4 | 2020 | 268 | 0.250 |
Why?
|
| Hospitals, Pediatric | 2 | 2024 | 21 | 0.250 |
Why?
|
| Feces | 2 | 2016 | 126 | 0.240 |
Why?
|
| Syphilis, Congenital | 1 | 2024 | 2 | 0.220 |
Why?
|
| United States | 7 | 2024 | 5072 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 358 | 0.200 |
Why?
|
| Methicillin | 1 | 2023 | 4 | 0.200 |
Why?
|
| Research Design | 1 | 2025 | 370 | 0.200 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2024 | 112 | 0.200 |
Why?
|
| Prevalence | 4 | 2017 | 1597 | 0.190 |
Why?
|
| Interleukin-10 | 1 | 2021 | 86 | 0.180 |
Why?
|
| Asthma | 2 | 2016 | 410 | 0.170 |
Why?
|
| Schools | 1 | 2023 | 283 | 0.170 |
Why?
|
| AIDS Serodiagnosis | 1 | 2000 | 25 | 0.160 |
Why?
|
| Specialization | 1 | 2020 | 26 | 0.160 |
Why?
|
| Mass Screening | 2 | 2021 | 531 | 0.150 |
Why?
|
| Chlamydia Infections | 1 | 2020 | 199 | 0.140 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 234 | 0.140 |
Why?
|
| Heparan Sulfate Proteoglycans | 1 | 1998 | 12 | 0.140 |
Why?
|
| Immunization, Secondary | 3 | 2025 | 15 | 0.140 |
Why?
|
| Skin Diseases, Bacterial | 1 | 2017 | 4 | 0.140 |
Why?
|
| Vulnerable Populations | 1 | 2019 | 163 | 0.140 |
Why?
|
| Herpesvirus 1, Human | 1 | 1998 | 64 | 0.140 |
Why?
|
| Clindamycin | 1 | 2017 | 13 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2019 | 245 | 0.130 |
Why?
|
| Virus Shedding | 1 | 2016 | 9 | 0.130 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2017 | 232 | 0.130 |
Why?
|
| Circovirus | 1 | 2016 | 11 | 0.130 |
Why?
|
| Mediastinal Diseases | 1 | 1996 | 1 | 0.120 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2016 | 45 | 0.120 |
Why?
|
| Incidence | 1 | 2019 | 1054 | 0.120 |
Why?
|
| Cross Protection | 1 | 2015 | 5 | 0.120 |
Why?
|
| Residence Characteristics | 1 | 2019 | 359 | 0.120 |
Why?
|
| RNA, Viral | 1 | 2016 | 317 | 0.110 |
Why?
|
| DNA, Viral | 1 | 2016 | 323 | 0.110 |
Why?
|
| Vaccines, Synthetic | 2 | 2025 | 78 | 0.110 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 2 | 2013 | 27 | 0.110 |
Why?
|
| Adult | 7 | 2025 | 13458 | 0.110 |
Why?
|
| Vaccines, Combined | 2 | 2023 | 11 | 0.110 |
Why?
|
| Diarrhea, Infantile | 1 | 2013 | 5 | 0.100 |
Why?
|
| Connecticut | 1 | 2011 | 11 | 0.090 |
Why?
|
| Pregnancy | 3 | 2024 | 1737 | 0.090 |
Why?
|
| Risk Factors | 3 | 2017 | 3942 | 0.090 |
Why?
|
| Minnesota | 1 | 2011 | 41 | 0.090 |
Why?
|
| Vaccines, Attenuated | 3 | 2016 | 75 | 0.090 |
Why?
|
| Adolescent | 2 | 2019 | 5950 | 0.080 |
Why?
|
| Neurons | 1 | 1998 | 1246 | 0.080 |
Why?
|
| Genotype | 1 | 2013 | 796 | 0.080 |
Why?
|
| HIV Infections | 1 | 2000 | 2535 | 0.060 |
Why?
|
| Middle Aged | 3 | 2025 | 11819 | 0.060 |
Why?
|
| Small-Area Analysis | 2 | 2016 | 10 | 0.060 |
Why?
|
| Syphilis Serodiagnosis | 1 | 2024 | 7 | 0.060 |
Why?
|
| Clinical Protocols | 1 | 2023 | 36 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2019 | 1574 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 708 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 3077 | 0.050 |
Why?
|
| Acute-Phase Proteins | 1 | 2021 | 15 | 0.050 |
Why?
|
| Linear Models | 1 | 2023 | 311 | 0.050 |
Why?
|
| Leukocyte Count | 1 | 2021 | 68 | 0.050 |
Why?
|
| Laboratories | 1 | 2021 | 40 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 1221 | 0.040 |
Why?
|
| Pregnancy, Ectopic | 1 | 2020 | 15 | 0.040 |
Why?
|
| Photoperiod | 1 | 2020 | 27 | 0.040 |
Why?
|
| Pelvic Inflammatory Disease | 1 | 2020 | 19 | 0.040 |
Why?
|
| Chicago | 1 | 2000 | 30 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2021 | 221 | 0.040 |
Why?
|
| Chlamydia | 1 | 2020 | 45 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2021 | 235 | 0.040 |
Why?
|
| Probability | 1 | 2000 | 82 | 0.040 |
Why?
|
| Decision Support Techniques | 1 | 2000 | 50 | 0.040 |
Why?
|
| Chlamydia muridarum | 1 | 2020 | 104 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2021 | 318 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2000 | 72 | 0.040 |
Why?
|
| Poverty | 1 | 2023 | 395 | 0.040 |
Why?
|
| Gas Gangrene | 1 | 1999 | 1 | 0.040 |
Why?
|
| Clostridium perfringens | 1 | 1999 | 4 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2000 | 176 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2023 | 1265 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2021 | 247 | 0.040 |
Why?
|
| Chondroitin ABC Lyase | 1 | 1998 | 2 | 0.040 |
Why?
|
| Polysaccharide-Lyases | 1 | 1998 | 10 | 0.040 |
Why?
|
| Galactosides | 1 | 1998 | 11 | 0.040 |
Why?
|
| Chick Embryo | 1 | 1998 | 77 | 0.040 |
Why?
|
| Heparin | 1 | 1998 | 39 | 0.040 |
Why?
|
| Texas | 1 | 2020 | 428 | 0.030 |
Why?
|
| Epithelium | 1 | 1998 | 78 | 0.030 |
Why?
|
| Vero Cells | 1 | 1998 | 109 | 0.030 |
Why?
|
| Urban Population | 1 | 2000 | 364 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 661 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 14 | 0.030 |
Why?
|
| Drainage | 1 | 2017 | 12 | 0.030 |
Why?
|
| Viral Envelope Proteins | 1 | 1998 | 90 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 174 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 506 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 431 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2017 | 305 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2020 | 362 | 0.030 |
Why?
|
| Indoles | 1 | 1998 | 178 | 0.030 |
Why?
|
| Nebulizers and Vaporizers | 1 | 2016 | 22 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 729 | 0.030 |
Why?
|
| Fibroblasts | 1 | 1998 | 278 | 0.030 |
Why?
|
| Astrocytes | 1 | 1998 | 244 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 224 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 249 | 0.030 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2000 | 471 | 0.030 |
Why?
|
| Air Pollution | 1 | 2016 | 87 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 1804 | 0.030 |
Why?
|
| Diarrhea | 1 | 2015 | 95 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1996 | 246 | 0.030 |
Why?
|
| Utilization Review | 1 | 2013 | 17 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 162 | 0.030 |
Why?
|
| Patient Admission | 1 | 2013 | 50 | 0.020 |
Why?
|
| Animals | 2 | 2020 | 16695 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 1848 | 0.020 |
Why?
|
| Mice | 1 | 2020 | 6490 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2013 | 1586 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 1999 | 46 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1999 | 26 | 0.010 |
Why?
|
| Genes, Bacterial | 1 | 1998 | 92 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 1998 | 207 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1998 | 454 | 0.010 |
Why?
|
| Pain | 1 | 1999 | 283 | 0.010 |
Why?
|
| Hospitalization | 1 | 1998 | 482 | 0.010 |
Why?
|